Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CDA; Dacart; LAPDAP + artesunate

Latest Information Update: 20 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Medicines for Malaria Venture; Special Programme for Research and Training in Tropical Diseases
  • Class Antimalarials; Artemisinins; Biguanides; Sesquiterpenes; Sulfones
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 08 Feb 2008 Chlorproguanil/dapsone/artesunate is still in phase III trials for uncomplicated malaria in sub-Saharan Africa
  • 26 Jul 2006 GlaxoSmithKline and Medicines for Malaria Venture have initiated two phase III trials for malaria in sub-Saharan Africa
  • 30 Nov 2005 Phase-III clinical trials in Malaria treatment in Africa (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top